section name header

Pronunciation

ve-cure-OH-nee-yum

Classifications

Therapeutic Classification: neuromuscular blocking agents-nondepolarizing

Indications

High Alert


Action

  • Prevents neuromuscular transmission by blocking the effect of acetylcholine at the myoneural junction. Has no analgesic or anxiolytic properties
Therapeutic effects:
  • Skeletal muscle paralysis.

Pharmacokinetics

Absorption: Following IV administration, absorption is essentially complete.

Distribution: Rapidly distributes in extracellular fluid; minimal penetration of the CNS.

Metabolism/Excretion: Some metabolism by the liver (20%), with conversion to at least one active metabolite; 35% excreted unchanged by the kidneys

Half-Life: Infants: 65 min; Children: 41 min; Adults: 65–75 min ( near term in pregnant patients, in hepatic impairment).

Time/Action Profile

ROUTEONSETPEAKDURATION
IV1–3 min3–5 min30–40 min





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

Resp: bronchospasm

Misc: ANAPHYLAXISALLERGIC REACTIONS INCLUDING

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Norcuron